Correction to: Translational Psychiatry
https://doi.org/10.1038/s41398-020-01095-8 published online 30 November 2020
The original version of this article unfortunately contained an error in the COI section. Unfortunately, P. M. Haddad’s COI statement was missed in the PDF although it was provided by the author. We apologize for this error. P. M. Haddad’s COI statement should be: PMH has received personal fees from Janssen, Lundbeck, NewBridge Pharmaceuticals, Otsuka, and Sunovion outside the submitted work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chaudhry, I.B., Husain, M.O., Khoso, A.B. et al. Correction: A randomised clinical trial of methotrexate points to possible efficacy and adaptive immune dysfunction in psychosis. Transl Psychiatry 11, 446 (2021). https://doi.org/10.1038/s41398-021-01449-w
Published:
DOI: https://doi.org/10.1038/s41398-021-01449-w
